Agios Pharm is a biotechnology business based in the US. Agios Pharm shares (AGIO) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $29.97 – an increase of 2.99% over the previous week. Agios Pharm employs 486 staff and has a trailing 12-month revenue of around $37 million.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $29.97 |
|---|---|
| 52-week range | $23.42 - $62.58 |
| 50-day moving average | $30.36 |
| 200-day moving average | $40.30 |
| Wall St. target price | $53.14 |
| PE ratio | 2.5859 |
| Dividend yield | N/A |
| Earnings per share (TTM) | $11.64 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $30.1 from 2025-05-02
| 1 week (2025-04-29) | 3.44% |
|---|---|
| 1 month (2025-04-07) | 16.22% |
| 3 months (2025-02-07) | -10.04% |
| 6 months (2024-11-07) | -45.35% |
| 1 year (2024-05-07) | -8.23% |
|---|---|
| 2 years (2023-05-05) | 17.85% |
| 3 years (2022-05-06) | 33.07% |
| 5 years (2020-05-06) | 38.81 |
Valuing Agios Pharm stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Agios Pharm's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Agios Pharm's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 3x. In other words, Agios Pharm shares trade at around 3x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
| Revenue TTM | $37 million |
|---|---|
| Gross profit TTM | $-272,996,992 |
| Return on assets TTM | -22.88% |
| Return on equity TTM | 60.26% |
| Profit margin | 1798.26% |
| Book value | $25.33 |
| Market Capitalization | $1.7 billion |
TTM: trailing 12 months
We're not expecting Agios Pharm to pay a dividend over the next 12 months.
Over the last 12 months, Agios Pharm's shares have ranged in value from as little as $23.415 up to $62.58. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Agios Pharm's is 0.828. This would suggest that Agios Pharm's shares are less volatile than average (for this exchange).
Agios Pharmaceuticals, Inc. , a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it develops tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and hemolytic anemias; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
SoFi, Robinhood, Tastytrade, Webull, Interactive Brokers, E*TRADE, eToro and others top our list for the best options trading platforms.
See our picks for the best brokers for trading S&P 500 stocks, ETFs, options and futures.
Our picks of the best brokerage accounts for index funds for beginners, teens, proprietary funds and more.
These are the stocks to buy when you don’t have much to spend.
Cash sweep accounts let you earn interest on your uninvested cash. Learn how they work and how to choose the best one here.
eToro is a robust trading platform with an easy-to-use interface and no commissions on stocks and ETFs.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
Thinking of switching from Moomoo? Here are 5 apps like Moomoo that offer valuable benefits
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
Webull is a broker with zero-commission trading and a suite of tools to help you invest.